Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study

Anna V Nikoghosyan, Irini Karapanagiotou-Schenkel, Marc W Münter, Alexandra D Jensen, Stephanie E Combs, Jürgen Debus, Anna V Nikoghosyan, Irini Karapanagiotou-Schenkel, Marc W Münter, Alexandra D Jensen, Stephanie E Combs, Jürgen Debus

Abstract

Background: Chordomas of the skull base are relative rare lesions of the bones. Surgical resection is the primary treatment standard, though complete resection is nearly impossible due to close proximity to critical and hence also dose limiting organs for radiation therapy. Level of recurrence after surgery alone is comparatively high, so adjuvant radiation therapy is very important for the improvement of local control rates. Proton therapy is the gold standard in the treatment of skull base chordomas. However, high-LET beams such as carbon ions theoretically offer biologic advantages by enhanced biologic effectiveness in slow-growing tumors.

Methods/design: This clinical study is a prospective randomised phase III trial. The trial will be carried out at Heidelberger Ionenstrahl-Therapie centre (HIT) and is a monocentric study.Patients with skull base chordoma will be randomised to either proton or carbon ion radiation therapy. As a standard, patients will undergo non-invasive, rigid immobilization and target volume delineation will be carried out based on CT and MRI data. The biologically isoeffective target dose to the PTV in carbon ion treatment (accelerated dose) will be 63 Gy E ± 5% and 72 Gy E ± 5% (standard dose) in proton therapy respectively. Local-progression free survival (LPFS) will be analysed as primary end point. Toxicity and overall survival are the secondary end points. Additional examined parameters are patterns of recurrence, prognostic factors and plan quality analysis.

Discussion: Up until now it was impossible to compare two different particle therapies, i.e. protons and carbon ions directly at the same facility.The aim of this study is to find out, whether the biological advantages of carbon ion therapy can also be clinically confirmed and translated into the better local control rates in the treatment of skull base chordomas.

Trial registration: ClinicalTrials.gov identifier: NCT01182779.

Figures

Figure 1
Figure 1
Typical dose distribution of carbon ion therapy by clivus chordoma patient (axial view and dose legend; red line defines CTV; both eyes, optic nerves and brain steam are also shown).

References

    1. McMaster. et al.Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Cases and Control. 2001;12:1–11. doi: 10.1023/A:1008947301735.
    1. Rosenberg. et al.Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma. Am J Surg Pathol. 1999;23(11):1370–8. doi: 10.1097/00000478-199911000-00007.
    1. Chugh. et al.Chordoma: the nonsarcoma primary bone tumor. Oncologist. 2007;12(11):1344–50. doi: 10.1634/theoncologist.12-11-1344.
    1. Heffelfinger. et al.Chordomas and cartilaginous tumors at the skull base. Cancer. 1973;32:410–420. doi: 10.1002/1097-0142(197308)32:2<410::AID-CNCR2820320219>;2-S.
    1. Borba. et al.Cranial chordomas in children and adolescence. J Neurosurg. 1996;84:584–91. doi: 10.3171/jns.1996.84.4.0584.
    1. Samii. et al.Chordomas of the skull base: surgical management and outcome. J Neurosurg. 2007;107(2):319–24. doi: 10.3171/JNS-07/08/0319.
    1. Noël. et al.Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol. 2005;44(7):700–8. doi: 10.1080/02841860500326257.
    1. Colli. et al.Chordomas of the skull base: follow-up review and prognostic factors. Neurosurg Focus. 2001;10(3):E1. doi: 10.3171/foc.2001.10.3.2.
    1. Noël. et al.Radiation therapy for chordoma and chondrosarcoma of the skull base and the cervical spine. Prognostic factors and patterns of failure. Strahlenther Onkol. 2003;179(4):241–8. doi: 10.1007/s00066-003-1065-5.
    1. Cho. et al.Chordomas and chondrosarcomas of the skull base: comparative analysis of clinical results in 30 patients. Neurosurg Rev. 2008;31:35–43. doi: 10.1007/s10143-007-0099-z.
    1. Casali. et al.Chordoma. Curr Opin Oncol. 2007;19(4):367–70. doi: 10.1097/CCO.0b013e3281214448.
    1. van Herk. Different styles of image-guided radiotherapy. Semin Radiat Oncol. 2007;17(4):258–67. doi: 10.1016/j.semradonc.2007.07.003.
    1. Munzenrider. et al.Proton therapy for tumors of the skull base. Strahlenther Onkol. 1999;175(2):57–63. doi: 10.1007/BF03038890.
    1. Hug. et al.Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg. 1999;91(3):432–9. doi: 10.3171/jns.1999.91.3.0432.
    1. Weber. et al.Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skulll base: the Paul Scherrer Institute experience. Int J Radiat Oncol Biol Phys. 2005;63:401–409.
    1. DeLaney, KooyProton and charged particle radiotherapy. 2008.
    1. Tsujii. et al.Clinical results of carbon ion therapy at NIRS. J Radiat Res. 2007;48:A1–A13. doi: 10.1269/jrr.48.A1.
    1. Schulz-Ertner. et al.Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys. 2007;68:449–457.
    1. Emami B, Lyman J, Brown A. et al.Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–122.
    1. Schoenfeld D. The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika. 1981;68:316–19. doi: 10.1093/biomet/68.1.316.
    1. Schoenfeld D. Sample-size formula for the proportional-hazards regression model. Biometrics. 1983;39:499–503. doi: 10.2307/2531021.
    1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481. doi: 10.2307/2281868.
    1. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187–220.
    1. Crowley J, Ankerest DP. Handbook of statistics in clinical oncology. 2. Chap-man & Hall/CRC; 2006.
    1. Fleiss JL. Statistical Methods for Rates and Proportions. Wiley, New York; 1981.
    1. Hartung K, Elpelt B. Statistik, Oldenbourg, 9. Auflage, München; 1993.
    1. Hosmer DW, Lemeshow D. Applied Logistic Regression. Wiley J, New York; 1989.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren